Loading clinical trials...
Loading clinical trials...
A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea
Conditions
Interventions
Ibodutant 10 mg
Placebo
Locations
127
United States
Huntsville, Alabama, United States
Sherwood, Arizona, United States
Little Rock, Arkansas, United States
Artesia, California, United States
Chula Vista, California, United States
Encino, California, United States
Start Date
March 1, 2014
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
January 19, 2017
NCT07103772
NCT03729271
NCT04855799
NCT03806959
NCT05130047
NCT05339243
Lead Sponsor
Menarini Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions